-
1
-
-
0037105599
-
Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma
-
Abe, M., Hiura, K., Wilde, J., Moriyama, K., Hashimoto, T., Ozaki, S., Wakatsuki, S., Kosaka, M., Kido, S., Inoue, D. & Matsumoto, T. (2002) Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma. Blood, 100, 2195-2202.
-
(2002)
Blood
, vol.100
, pp. 2195-2202
-
-
Abe, M.1
Hiura, K.2
Wilde, J.3
Moriyama, K.4
Hashimoto, T.5
Ozaki, S.6
Wakatsuki, S.7
Kosaka, M.8
Kido, S.9
Inoue, D.10
Matsumoto, T.11
-
2
-
-
4944230728
-
Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion
-
Abe, M., Hiura, K., Wilde, J., Shioyasono, A., Moriyama, K., Hashimoto, T., Kido, S., Oshima, T., Shibata, H., Ozaki, S., Inoue, D. & Matsumoto, T. (2004) Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood, 104, 2484-2491.
-
(2004)
Blood
, vol.104
, pp. 2484-2491
-
-
Abe, M.1
Hiura, K.2
Wilde, J.3
Shioyasono, A.4
Moriyama, K.5
Hashimoto, T.6
Kido, S.7
Oshima, T.8
Shibata, H.9
Ozaki, S.10
Inoue, D.11
Matsumoto, T.12
-
3
-
-
33846031926
-
The molecular understanding of osteoclast differentiation
-
Asagiri, M. & Takayanagi, H. (2007) The molecular understanding of osteoclast differentiation. Bone, 40, 251-264.
-
(2007)
Bone
, vol.40
, pp. 251-264
-
-
Asagiri, M.1
Takayanagi, H.2
-
4
-
-
77949894706
-
Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences
-
Barlogie, B., Attal, M., Crowley, J., van Rhee, F., Szymonifka, J., Moreau, P., Durie, B.G. & Harousseau, J.L. (2010) Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences. Journal of Clinical Oncology, 28, 1209-1214.
-
(2010)
Journal of Clinical Oncology
, vol.28
, pp. 1209-1214
-
-
Barlogie, B.1
Attal, M.2
Crowley, J.3
van Rhee, F.4
Szymonifka, J.5
Moreau, P.6
Durie, B.G.7
Harousseau, J.L.8
-
5
-
-
0020552997
-
Saccharides mediate the attachment of rat macrophages to bone in vitro
-
Bar-Shavit, Z., Teitelbaum, S.L. & Kahn, A.J. (1983) Saccharides mediate the attachment of rat macrophages to bone in vitro. Journal of Clinical Investigation, 72, 516-525.
-
(1983)
Journal of Clinical Investigation
, vol.72
, pp. 516-525
-
-
Bar-Shavit, Z.1
Teitelbaum, S.L.2
Kahn, A.J.3
-
6
-
-
0030888689
-
Antiproliferative activity in vitro and in vivo of the spicamycin analogue KRN5500 with altered glycoprotein expression in vitro
-
Burger, A.M., Kaur, G., Hollingshead, M., Fischer, R.T., Nagashima, K., Malspeis, L., Duncan, K.L. & Sausville, E.A. (1997) Antiproliferative activity in vitro and in vivo of the spicamycin analogue KRN5500 with altered glycoprotein expression in vitro. Clinical Cancer Research, 3, 455-463.
-
(1997)
Clinical Cancer Research
, vol.3
, pp. 455-463
-
-
Burger, A.M.1
Kaur, G.2
Hollingshead, M.3
Fischer, R.T.4
Nagashima, K.5
Malspeis, L.6
Duncan, K.L.7
Sausville, E.A.8
-
7
-
-
0037804761
-
KRN5500: a novel therapeutic agent with in vitro activity against human B-cell chronic lymphocytic leukemia cells mediates cytotoxicity via the intrinsic pathway of apoptosis
-
Byrd, J.C., Lucas, D.M., Mone, A.P., Kitner, J.B., Drabick, J.J. & Grever, M.R. (2003) KRN5500: a novel therapeutic agent with in vitro activity against human B-cell chronic lymphocytic leukemia cells mediates cytotoxicity via the intrinsic pathway of apoptosis. Blood, 101, 4547-4550.
-
(2003)
Blood
, vol.101
, pp. 4547-4550
-
-
Byrd, J.C.1
Lucas, D.M.2
Mone, A.P.3
Kitner, J.B.4
Drabick, J.J.5
Grever, M.R.6
-
8
-
-
34948890040
-
Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells
-
Davenport, E.L., Moore, H.E., Dunlop, A.S., Sharp, S.Y., Workman, P., Morgan, G.J. & Davies, F.E. (2007) Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells. Blood, 110, 2641-2649.
-
(2007)
Blood
, vol.110
, pp. 2641-2649
-
-
Davenport, E.L.1
Moore, H.E.2
Dunlop, A.S.3
Sharp, S.Y.4
Workman, P.5
Morgan, G.J.6
Davies, F.E.7
-
9
-
-
0037072533
-
A water-soluble synthetic spicamycin derivative (San-Gly) decreases mechanical allodynia in a rodent model of neuropathic pain
-
DiLorenzo, L., Kobierski, L., Moore, K.A. & Borsook, D. (2002) A water-soluble synthetic spicamycin derivative (San-Gly) decreases mechanical allodynia in a rodent model of neuropathic pain. Neuroscience Letters, 330, 37-40.
-
(2002)
Neuroscience Letters
, vol.330
, pp. 37-40
-
-
DiLorenzo, L.1
Kobierski, L.2
Moore, K.A.3
Borsook, D.4
-
10
-
-
36349023319
-
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
-
Dimopoulos, M., Spencer, A., Attal, M., Prince, H.M., Harousseau, J.L., Dmoszynska, A., San Miguel, J., Hellmann, A., Facon, T., Foa, R., Corso, A., Masliak, Z., Olesnyckyj, M., Yu, Z., Patin, J., Zeldis, J.B. & Knight, R.D. (2007) Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. New England Journal of Medicine, 357, 2123-2132.
-
(2007)
New England Journal of Medicine
, vol.357
, pp. 2123-2132
-
-
Dimopoulos, M.1
Spencer, A.2
Attal, M.3
Prince, H.M.4
Harousseau, J.L.5
Dmoszynska, A.6
San Miguel, J.7
Hellmann, A.8
Facon, T.9
Foa, R.10
Corso, A.11
Masliak, Z.12
Olesnyckyj, M.13
Yu, Z.14
Patin, J.15
Zeldis, J.B.16
Knight, R.D.17
-
11
-
-
0023159808
-
Inhibitors of the biosynthesis and processing of N-linked oligosaccharide chains
-
Elbein, A.D. (1987) Inhibitors of the biosynthesis and processing of N-linked oligosaccharide chains. Annual Review of Biochemistry, 56, 497-534.
-
(1987)
Annual Review of Biochemistry
, vol.56
, pp. 497-534
-
-
Elbein, A.D.1
-
12
-
-
0021033184
-
Studies on the differentiation inducers of myeloid leukemic cells. III. Spicamycin, a new inducer of differentiation of HL-60 human promyelocytic leukemia cells
-
Hayakawa, Y., Nakagawa, M., Kawai, H., Tanabe, K., Nakayama, H., Shimazu, A., Seto, H. & Otake, N. (1983) Studies on the differentiation inducers of myeloid leukemic cells. III. Spicamycin, a new inducer of differentiation of HL-60 human promyelocytic leukemia cells. The Journal of antibiotics (Tokyo), 36, 934-937.
-
(1983)
The Journal of antibiotics (Tokyo)
, vol.36
, pp. 934-937
-
-
Hayakawa, Y.1
Nakagawa, M.2
Kawai, H.3
Tanabe, K.4
Nakayama, H.5
Shimazu, A.6
Seto, H.7
Otake, N.8
-
13
-
-
0027493092
-
Structure-antitumor activity relationship of semi-synthetic spicamycin analogues
-
Kamishohara, M., Kawai, H., Odagawa, A., Isoe, T., Mochizuki, J., Uchida, T., Hayakawa, Y., Seto, H., Tsuruo, T. & Otake, N. (1993) Structure-antitumor activity relationship of semi-synthetic spicamycin analogues. The Journal of antibiotics (Tokyo), 46, 1439-1446.
-
(1993)
The Journal of antibiotics (Tokyo)
, vol.46
, pp. 1439-1446
-
-
Kamishohara, M.1
Kawai, H.2
Odagawa, A.3
Isoe, T.4
Mochizuki, J.5
Uchida, T.6
Hayakawa, Y.7
Seto, H.8
Tsuruo, T.9
Otake, N.10
-
14
-
-
0028065513
-
Antitumor activity of a spicamycin derivative, KRN5500, and its active metabolite in tumor cells
-
Kamishohara, M., Kawai, H., Sakai, T., Isoe, T., Hasegawa, K., Mochizuki, J., Uchida, T., Kataoka, S., Yamaki, H., Tsuruo, T. & Otake, N. (1994) Antitumor activity of a spicamycin derivative, KRN5500, and its active metabolite in tumor cells. Oncology Research, 6, 383-390.
-
(1994)
Oncology Research
, vol.6
, pp. 383-390
-
-
Kamishohara, M.1
Kawai, H.2
Sakai, T.3
Isoe, T.4
Hasegawa, K.5
Mochizuki, J.6
Uchida, T.7
Kataoka, S.8
Yamaki, H.9
Tsuruo, T.10
Otake, N.11
-
15
-
-
0029797131
-
Inhibitory effect of a spicamycin derivative, KRN5500, on the growth of hepatic metastasis of human colon cancer-producing tissue polypeptide antigen
-
Kamishohara, M., Kawai, H., Sakai, T., Uchida, T., Tsuruo, T. & Otake, N. (1996) Inhibitory effect of a spicamycin derivative, KRN5500, on the growth of hepatic metastasis of human colon cancer-producing tissue polypeptide antigen. Cancer Chemotherapy and Pharmacology, 38, 495-498.
-
(1996)
Cancer Chemotherapy and Pharmacology
, vol.38
, pp. 495-498
-
-
Kamishohara, M.1
Kawai, H.2
Sakai, T.3
Uchida, T.4
Tsuruo, T.5
Otake, N.6
-
16
-
-
0034192203
-
Selective accumulation of the endoplasmic reticulum-Golgi intermediate compartment induced by the antitumor drug KRN5500
-
Kamishohara, M., Kenney, S., Domergue, R., Vistica, D.T. & Sausville, E.A. (2000) Selective accumulation of the endoplasmic reticulum-Golgi intermediate compartment induced by the antitumor drug KRN5500. Experimental Cell Research, 256, 468-479.
-
(2000)
Experimental Cell Research
, vol.256
, pp. 468-479
-
-
Kamishohara, M.1
Kenney, S.2
Domergue, R.3
Vistica, D.T.4
Sausville, E.A.5
-
17
-
-
0034161257
-
KRN5500, a novel antitumor agent, induces apoptosis or cell differentiation in HL-60 cells
-
Kawasaki, K., Murakami, T., Ita, M., Sasaki, K. & Furukawa, S. (2000) KRN5500, a novel antitumor agent, induces apoptosis or cell differentiation in HL-60 cells. Cytometry, 39, 211-216.
-
(2000)
Cytometry
, vol.39
, pp. 211-216
-
-
Kawasaki, K.1
Murakami, T.2
Ita, M.3
Sasaki, K.4
Furukawa, S.5
-
18
-
-
42449114035
-
Multiple myeloma
-
Kyle, R.A. & Rajkumar, S.V. (2008) Multiple myeloma. Blood, 111, 2962-2972.
-
(2008)
Blood
, vol.111
, pp. 2962-2972
-
-
Kyle, R.A.1
Rajkumar, S.V.2
-
19
-
-
0028913674
-
In vitro cytotoxicity of a novel antitumor antibiotic, spicamycin derivative, in human lung cancer cell lines
-
Lee, Y.S., Nishio, K., Ogasawara, H., Funayama, Y., Ohira, T. & Saijo, N. (1995) In vitro cytotoxicity of a novel antitumor antibiotic, spicamycin derivative, in human lung cancer cell lines. Cancer Research, 55, 1075-1079.
-
(1995)
Cancer Research
, vol.55
, pp. 1075-1079
-
-
Lee, Y.S.1
Nishio, K.2
Ogasawara, H.3
Funayama, Y.4
Ohira, T.5
Saijo, N.6
-
20
-
-
0043193876
-
Proteasome inhibitors disrupt the unfolded protein response in myeloma cells
-
Lee, A.H., Iwakoshi, N.N., Anderson, K.C. & Glimcher, L.H. (2003) Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proceedings of the National Academy of Sciences of the United States of America, 100, 9946-9951.
-
(2003)
Proceedings of the National Academy of Sciences of the United States of America
, vol.100
, pp. 9946-9951
-
-
Lee, A.H.1
Iwakoshi, N.N.2
Anderson, K.C.3
Glimcher, L.H.4
-
21
-
-
33847714599
-
Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition
-
Meister, S., Schubert, U., Neubert, K., Herrmann, K., Burger, R., Gramatzki, M., Hahn, S., Schreiber, S., Wilhelm, S., Herrmann, M., Jack, H.M. & Voll, R.E. (2007) Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Research, 67, 1783-1792.
-
(2007)
Cancer Research
, vol.67
, pp. 1783-1792
-
-
Meister, S.1
Schubert, U.2
Neubert, K.3
Herrmann, K.4
Burger, R.5
Gramatzki, M.6
Hahn, S.7
Schreiber, S.8
Wilhelm, S.9
Herrmann, M.10
Jack, H.M.11
Voll, R.E.12
-
22
-
-
33744539521
-
Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells
-
Obeng, E.A., Carlson, L.M., Gutman, D.M., Harrington, Jr, W.J., Lee, K.P. & Boise, L.H. (2006) Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood, 107, 4907-4916.
-
(2006)
Blood
, vol.107
, pp. 4907-4916
-
-
Obeng, E.A.1
Carlson, L.M.2
Gutman, D.M.3
Harrington Jr., W.J.4
Lee, K.P.5
Boise, L.H.6
-
23
-
-
27644473781
-
Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2
-
Oshima, T., Abe, M., Asano, J., Hara, T., Kitazoe, K., Sekimoto, E., Tanaka, Y., Shibata, H., Hashimoto, T., Ozaki, S., Kido, S., Inoue, D. & Matsumoto, T. (2005) Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood, 106, 3160-3165.
-
(2005)
Blood
, vol.106
, pp. 3160-3165
-
-
Oshima, T.1
Abe, M.2
Asano, J.3
Hara, T.4
Kitazoe, K.5
Sekimoto, E.6
Tanaka, Y.7
Shibata, H.8
Hashimoto, T.9
Ozaki, S.10
Kido, S.11
Inoue, D.12
Matsumoto, T.13
-
24
-
-
20444433230
-
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
-
Richardson, P.G., Sonneveld, P., Schuster, M.W., Irwin, D., Stadtmauer, E.A., Facon, T., Harousseau, J.L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., Reece, D., San-Miguel, J.F., Blade, J., Boccadoro, M., Cavenagh, J., Dalton, W.S., Boral, A.L., Esseltine, D.L., Porter, J.B., Schenkein, D. & Anderson, K.C. (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. New England Journal of Medicine, 352, 2487-2498.
-
(2005)
New England Journal of Medicine
, vol.352
, pp. 2487-2498
-
-
Richardson, P.G.1
Sonneveld, P.2
Schuster, M.W.3
Irwin, D.4
Stadtmauer, E.A.5
Facon, T.6
Harousseau, J.L.7
Ben-Yehuda, D.8
Lonial, S.9
Goldschmidt, H.10
Reece, D.11
San-Miguel, J.F.12
Blade, J.13
Boccadoro, M.14
Cavenagh, J.15
Dalton, W.S.16
Boral, A.L.17
Esseltine, D.L.18
Porter, J.B.19
Schenkein, D.20
Anderson, K.C.21
more..
-
25
-
-
34250899722
-
Signal integration in the endoplasmic reticulum unfolded protein response
-
Ron, D. & Walter, P. (2007) Signal integration in the endoplasmic reticulum unfolded protein response. Nature Reviews. Molecular Cell Biology, 8, 519-529.
-
(2007)
Nature Reviews. Molecular Cell Biology
, vol.8
, pp. 519-529
-
-
Ron, D.1
Walter, P.2
-
26
-
-
0029619540
-
Structure-antitumor activity relationship of semi-synthetic Spicamycin derivatives
-
Sakai, T., Kawai, H., Kamishohara, M., Odagawa, A., Suzuki, A., Uchida, T., Kawasaki, T., Tsuruo, T. & Otake, N. (1995) Structure-antitumor activity relationship of semi-synthetic Spicamycin derivatives. The Journal of antibiotics (Tokyo), 48, 1467-1480.
-
(1995)
The Journal of antibiotics (Tokyo)
, vol.48
, pp. 1467-1480
-
-
Sakai, T.1
Kawai, H.2
Kamishohara, M.3
Odagawa, A.4
Suzuki, A.5
Uchida, T.6
Kawasaki, T.7
Tsuruo, T.8
Otake, N.9
-
27
-
-
33847057383
-
A single-chain Fv diabody against human leukocyte antigen-A molecules specifically induces myeloma cell death in the bone marrow environment
-
Sekimoto, E., Ozaki, S., Ohshima, T., Shibata, H., Hashimoto, T., Abe, M., Kimura, N., Hattori, K., Kawai, S., Kinoshita, Y., Yamada-Okabe, H., Tsuchiya, M. & Matsumoto, T. (2007) A single-chain Fv diabody against human leukocyte antigen-A molecules specifically induces myeloma cell death in the bone marrow environment. Cancer Research, 67, 1184-1192.
-
(2007)
Cancer Research
, vol.67
, pp. 1184-1192
-
-
Sekimoto, E.1
Ozaki, S.2
Ohshima, T.3
Shibata, H.4
Hashimoto, T.5
Abe, M.6
Kimura, N.7
Hattori, K.8
Kawai, S.9
Kinoshita, Y.10
Yamada-Okabe, H.11
Tsuchiya, M.12
Matsumoto, T.13
-
28
-
-
0032748385
-
Antitumor activity of thalidomide in refractory multiple myeloma
-
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., Zeddis, J. & Barlogie, B. (1999) Antitumor activity of thalidomide in refractory multiple myeloma. New England Journal of Medicine, 341, 1565-1571.
-
(1999)
New England Journal of Medicine
, vol.341
, pp. 1565-1571
-
-
Singhal, S.1
Mehta, J.2
Desikan, R.3
Ayers, D.4
Roberson, P.5
Eddlemon, P.6
Munshi, N.7
Anaissie, E.8
Wilson, C.9
Dhodapkar, M.10
Zeddis, J.11
Barlogie, B.12
-
29
-
-
0034284212
-
KRN5500 induces apoptosis (PCD) of myeloid leukemia cell lines and patient blasts
-
Stine, K.C., Warren, B.A., Saylors, R.L. & Becton, D.L. (2000) KRN5500 induces apoptosis (PCD) of myeloid leukemia cell lines and patient blasts. Leukemia Research, 24, 741-749.
-
(2000)
Leukemia Research
, vol.24
, pp. 741-749
-
-
Stine, K.C.1
Warren, B.A.2
Saylors, R.L.3
Becton, D.L.4
-
30
-
-
0242525649
-
Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors
-
Supko, J.G., Eder, Jr, J.P., Ryan, D.P., Seiden, M.V., Lynch, T.J., Amrein, P.C., Kufe, D.W. & Clark, J.W. (2003) Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors. Clinical Cancer Research, 9, 5178-5186.
-
(2003)
Clinical Cancer Research
, vol.9
, pp. 5178-5186
-
-
Supko, J.G.1
Eder Jr., J.P.2
Ryan, D.P.3
Seiden, M.V.4
Lynch, T.J.5
Amrein, P.C.6
Kufe, D.W.7
Clark, J.W.8
-
31
-
-
0037012864
-
Total synthesis of spicamycin
-
Suzuki, T., Suzuki, S.T., Yamada, I., Koashi, Y., Yamada, K. & Chida, N. (2002) Total synthesis of spicamycin. Journal of Organic Chemistry, 67, 2874-2880.
-
(2002)
Journal of Organic Chemistry
, vol.67
, pp. 2874-2880
-
-
Suzuki, T.1
Suzuki, S.T.2
Yamada, I.3
Koashi, Y.4
Yamada, K.5
Chida, N.6
-
32
-
-
0035040920
-
Population pharmacokinetic modeling and model validation of a spicamycin derivative, KRN5500, in phase 1 study
-
Takama, H., Tanaka, H., Sudo, T., Tamura, T. & Tanigawara, Y. (2001) Population pharmacokinetic modeling and model validation of a spicamycin derivative, KRN5500, in phase 1 study. Cancer Chemotherapy and Pharmacology, 47, 404-410.
-
(2001)
Cancer Chemotherapy and Pharmacology
, vol.47
, pp. 404-410
-
-
Takama, H.1
Tanaka, H.2
Sudo, T.3
Tamura, T.4
Tanigawara, Y.5
-
33
-
-
78650305162
-
Tgf-Beta inhibition restores terminal osteoblast differentiation to suppress myeloma growth
-
Takeuchi, K., Abe, M., Hiasa, M., Oda, A., Amou, H., Kido, S., Harada, T., Tanaka, O., Miki, H., Nakamura, S., Nakano, A., Kagawa, K., Yata, K., Ozaki, S. & Matsumoto, T. (2010) Tgf-Beta inhibition restores terminal osteoblast differentiation to suppress myeloma growth. PLoS ONE, 5, e9870.
-
(2010)
PLoS ONE
, vol.5
-
-
Takeuchi, K.1
Abe, M.2
Hiasa, M.3
Oda, A.4
Amou, H.5
Kido, S.6
Harada, T.7
Tanaka, O.8
Miki, H.9
Nakamura, S.10
Nakano, A.11
Kagawa, K.12
Yata, K.13
Ozaki, S.14
Matsumoto, T.15
-
34
-
-
20344381988
-
A clinically relevant SCID-hu in vivo model of human multiple myeloma
-
Tassone, P., Neri, P., Carrasco, D.R., Burger, R., Goldmacher, V.S., Fram, R., Munshi, V., Shammas, M.A., Catley, L., Jacob, G.S., Venuta, S., Anderson, K.C. & Munshi, N.C. (2005) A clinically relevant SCID-hu in vivo model of human multiple myeloma. Blood, 106, 713-716.
-
(2005)
Blood
, vol.106
, pp. 713-716
-
-
Tassone, P.1
Neri, P.2
Carrasco, D.R.3
Burger, R.4
Goldmacher, V.S.5
Fram, R.6
Munshi, V.7
Shammas, M.A.8
Catley, L.9
Jacob, G.S.10
Venuta, S.11
Anderson, K.C.12
Munshi, N.C.13
-
35
-
-
36349010285
-
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America
-
Weber, D.M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E.A., Siegel, D., Borrello, I., Rajkumar, S.V., Chanan-Khan, A.A., Lonial, S., Yu, Z., Patin, J., Olesnyckyj, M., Zeldis, J.B. & Knight, R.D. (2007) Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. New England Journal of Medicine, 357, 2133-2142.
-
(2007)
New England Journal of Medicine
, vol.357
, pp. 2133-2142
-
-
Weber, D.M.1
Chen, C.2
Niesvizky, R.3
Wang, M.4
Belch, A.5
Stadtmauer, E.A.6
Siegel, D.7
Borrello, I.8
Rajkumar, S.V.9
Chanan-Khan, A.A.10
Lonial, S.11
Yu, Z.12
Patin, J.13
Olesnyckyj, M.14
Zeldis, J.B.15
Knight, R.D.16
-
36
-
-
21744457447
-
Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival
-
Wuilleme-Toumi, S., Robillard, N., Gomez, P., Moreau, P., Le Gouill, S., Avet-Loiseau, H., Harousseau, J.L., Amiot, M. & Bataille, R. (2005) Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia, 19, 1248-1252.
-
(2005)
Leukemia
, vol.19
, pp. 1248-1252
-
-
Wuilleme-Toumi, S.1
Robillard, N.2
Gomez, P.3
Moreau, P.4
Le Gouill, S.5
Avet-Loiseau, H.6
Harousseau, J.L.7
Amiot, M.8
Bataille, R.9
-
37
-
-
0042284740
-
Phase I and pharmacokinetic study of KRN5500, a spicamycin derivative, for patients with advanced solid tumors
-
Yamamoto, N., Tamura, T., Kamiya, Y., Ono, H., Kondoh, H., Shirao, K., Matsumura, Y., Tanigawara, Y. & Shimada, Y. (2003) Phase I and pharmacokinetic study of KRN5500, a spicamycin derivative, for patients with advanced solid tumors. Japanese Journal of Clinical Oncology, 33, 302-308.
-
(2003)
Japanese Journal of Clinical Oncology
, vol.33
, pp. 302-308
-
-
Yamamoto, N.1
Tamura, T.2
Kamiya, Y.3
Ono, H.4
Kondoh, H.5
Shirao, K.6
Matsumura, Y.7
Tanigawara, Y.8
Shimada, Y.9
-
38
-
-
8844264524
-
The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells
-
Yata, K. & Yaccoby, S. (2004) The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells. Leukemia, 18, 1891-1897.
-
(2004)
Leukemia
, vol.18
, pp. 1891-1897
-
-
Yata, K.1
Yaccoby, S.2
-
39
-
-
32644432826
-
pXBP1(U) encoded in XBP1 pre-mRNA negatively regulates unfolded protein response activator pXBP1(S) in mammalian ER stress response
-
Yoshida, H., Oku, M., Suzuki, M. & Mori, K. (2006) pXBP1(U) encoded in XBP1 pre-mRNA negatively regulates unfolded protein response activator pXBP1(S) in mammalian ER stress response. Journal of Cell Biology, 172, 565-575.
-
(2006)
Journal of Cell Biology
, vol.172
, pp. 565-575
-
-
Yoshida, H.1
Oku, M.2
Suzuki, M.3
Mori, K.4
-
40
-
-
0033945247
-
Spicamycin and KRN5500 induce apoptosis in myeloid and lymphoid cell lines with down-regulation of bcl-2 expression and modulation of promyelocytic leukemia protein
-
Zhang, W.J., Ohnishi, K., Yoshida, H., Pan, L., Maksumova, L., Muratkhodjaev, F., Luo, J.M., Shigeno, K., Fujisawa, S., Naito, K., Nakamura, S., Shinjo, K., Takeshita, A. & Ohno, R. (2000) Spicamycin and KRN5500 induce apoptosis in myeloid and lymphoid cell lines with down-regulation of bcl-2 expression and modulation of promyelocytic leukemia protein. Japanese Journal of Cancer Research, 91, 604-611.
-
(2000)
Japanese Journal of Cancer Research
, vol.91
, pp. 604-611
-
-
Zhang, W.J.1
Ohnishi, K.2
Yoshida, H.3
Pan, L.4
Maksumova, L.5
Muratkhodjaev, F.6
Luo, J.M.7
Shigeno, K.8
Fujisawa, S.9
Naito, K.10
Nakamura, S.11
Shinjo, K.12
Takeshita, A.13
Ohno, R.14
-
41
-
-
0037085778
-
Myeloid cell factor-1 is a critical survival factor for multiple myeloma
-
Zhang, B., Gojo, I. & Fenton, R.G. (2002) Myeloid cell factor-1 is a critical survival factor for multiple myeloma. Blood, 99, 1885-1893.
-
(2002)
Blood
, vol.99
, pp. 1885-1893
-
-
Zhang, B.1
Gojo, I.2
Fenton, R.G.3
|